Compare MATX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | CRSP |
|---|---|---|
| Founded | 1882 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.0B |
| IPO Year | 1994 | 2016 |
| Metric | MATX | CRSP |
|---|---|---|
| Price | $212.94 | $47.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $163.33 | $70.29 |
| AVG Volume (30 Days) | 281.9K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $3,344,500,000.00 | $289,590,000.00 |
| Revenue This Year | $4.65 | $807.72 |
| Revenue Next Year | $4.31 | $172.52 |
| P/E Ratio | $116.70 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $86.97 | $44.12 |
| 52 Week High | $230.74 | $78.48 |
| Indicator | MATX | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 36.92 |
| Support Level | $189.60 | $46.15 |
| Resistance Level | $230.74 | $60.10 |
| Average True Range (ATR) | 7.54 | 2.64 |
| MACD | 0.27 | -0.97 |
| Stochastic Oscillator | 49.19 | 2.56 |
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.